ArriVent BioPharma, Inc.
AVBP
$29.79
-$0.49-1.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 21.87% | 27.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.27% | 18.77% | |||
| Operating Income | -14.27% | -18.77% | |||
| Income Before Tax | -15.17% | -20.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.17% | -20.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.17% | -20.46% | |||
| EBIT | -14.27% | -18.77% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -9.03% | -14.78% | |||
| Normalized Basic EPS | -9.02% | -16.14% | |||
| EPS Diluted | -9.03% | -14.78% | |||
| Normalized Diluted EPS | -9.02% | -16.14% | |||
| Average Basic Shares Outstanding | 5.63% | 4.95% | |||
| Average Diluted Shares Outstanding | 5.63% | 4.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||